Afghan Border Closure Sends Pakistan's Pharma Exports Tumbling
Pakistan's drug exports have taken a heavy hit as trade with Afghanistan has been brought to a standstill. Pharmaceutical shipments dropped by 30.26 percent during fiscal year 2025-26, and the slide continued into the first quarter of fiscal year 2026-27, when export value fell a further 25.53 percent.
Industry representatives say the suspension of trade with Afghanistan is the main factor behind the slump. Local media reports note that Afghanistan has been among the most important overseas markets for Pakistan's pharmaceutical manufacturers for many years, and the closure of the border has disrupted business activity across the sector.
Official data reveals that pharmaceutical export earnings slipped to 31.90 crore dollars in fiscal year 2025-26 from 45.74 crore dollars the previous year. In absolute terms, the shortfall stands at 13.84 crore dollars.
Shipment volumes have also shrunk considerably. In fiscal year 2024-25, Pakistan exported 1,12,517 metric tonnes of pharmaceutical goods. That figure declined to 83,104 metric tonnes in fiscal year 2025-26, a reduction of 29,413 metric tonnes or 26.14 percent.
The contraction has persisted into the current fiscal year. From July to September 2026, drug exports came to 7.33 crore dollars, compared with 9.84 crore dollars in the corresponding period of fiscal year 2025-26. The resulting loss of 2.51 crore dollars amounts to a 25.53 percent decline in export income.
It is worth noting that these figures exclude surgical products and medical equipment.
According to additional reports, Afghanistan alone accounted for medicine exports worth 15.568 crore dollars in fiscal year 2024-25. This represented around 34.1 percent of Pakistan's total pharmaceutical exports that year, underlining how heavily the industry depended on this single market.
Former PPMA chairman Tauqeer ul Haq said the halt in trade has inflicted serious damage on both the drug sector and the national treasury. He also warned that Afghan patients are being pushed toward more expensive medicines as a result.
The Pakistan Pharmaceutical Manufacturers Association has taken up the matter with the government. Federal Planning Minister Ahsan Iqbal had promised to raise the issue with concerned officials and explore ways to restart drug exports to Afghanistan. Haq, however, voiced frustration at the absence of any concrete follow-up.
The dispute between the two neighbours is rooted in history. The Durand Line, demarcated during British rule to set the border between British India and Afghanistan, is a central source of disagreement.
Bilateral ties worsened after the Taliban regained power in August 2021. Islamabad has repeatedly alleged that Afghan territory is being used by groups such as Tehreek-e-Taliban Pakistan (TTP) and Islamic State-Khorasan (ISIS-K) to launch attacks inside Pakistan. Kabul denies these claims and accuses Pakistan of blaming it for domestic security troubles.
The border has been shut since October 2025 following cross-border violence. The closure has pushed up prices of goods, made cross-border travel for medical care difficult, and hurt local incomes. It has also strained diplomatic relations and forced traders to look for alternative regional routes.
Meanwhile, reports from Kabul suggest that Afghanistan had long relied heavily on Pakistan for its medicine supply. The current tensions have exposed the risks of that dependence, and Afghanistan is now turning to other suppliers, a move that adds to the difficulties facing Pakistan's pharmaceutical industry.